With TransCode go­ing pub­lic, in­dus­try sur­pass­es $10B IPO mark; Galect­in's in­hibitor shows PhIb suc­cess in can­cer treat­ment

TransCode Ther­a­peu­tics has priced its IPO at $4 a share, and while that num­ber might be on the small­er end of IPOs this year, it sig­ni­fies the pass­ing of the $10 bil­lion mark for the in­dus­try.

With $10 bil­lion raised in pub­lic of­fer­ings so far this year, the biotech mar­ket is well on track to sur­pass its record to­tals for last year. (For more on biotech’s red-hot IPO space, book­mark our track­er here.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER